| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Sofosbuvir impurity G does not have a defined pharmacological target as it is an impurity standard, not a therapeutic agent. Its related compound, Sofosbuvir, targets the HCV NS5B RNA-dependent RNA polymerase, inhibiting viral RNA replication. The impurity itself is used for analytical purposes.
|
|---|---|
| ln Vitro |
In vitro activity of Sofosbuvir impurity G as a standalone compound has not been characterized, as it is not intended for biological studies. The related compound, Sofosbuvir, displays potent activity against hepatitis C virus by inhibiting HCV RNA replication.
|
| ln Vivo |
In vivo activity of Sofosbuvir impurity G as a standalone compound has not been characterized. The compound is used as an analytical standard and is not intended for in vivo studies. Its related compound, Sofosbuvir, is an approved anti-HCV drug with established in vivo efficacy.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays are not applicable to Sofosbuvir impurity G, as it is not a bioactive molecule. It is a chemical standard used for analytical method development and quality control.
|
| Cell Assay |
In vitro cell-based assays are not applicable to Sofosbuvir impurity G. The compound is used as a reference standard in analytical chemistry, not for cell-based studies.
|
| Animal Protocol |
In vivo animal studies are not applicable to Sofosbuvir impurity G. The compound is not intended for administration to animals. It is used exclusively as an analytical standard.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of Sofosbuvir impurity G have not been characterized, as it is not a therapeutic agent. The compound is used as an analytical standard for quality control purposes. It is soluble in DMSO at ~100 mg/mL and should be stored at -20°C.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Sofosbuvir impurity G has not been characterized. The compound is intended for research use only and is not approved for human therapeutic applications.
|
| Additional Infomation |
Sofosbuvir impurity G is a research-grade chemical used as a reference standard for the analytical testing of Sofosbuvir. It is a diastereomer of Sofosbuvir. The compound is supplied as a white to off-white solid powder with a purity of ≥98%.
|
| Molecular Formula |
C22H29FN3O9P
|
|---|---|
| Molecular Weight |
529.452530622482
|
| Exact Mass |
529.162
|
| CAS # |
1337482-15-1
|
| PubChem CID |
58463528
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Index of Refraction |
1.573
|
| LogP |
1.79
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
36
|
| Complexity |
913
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
[P@@](N([H])[C@]([H])(C(=O)OC([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])[H])(=O)(OC1C([H])=C([H])C([H])=C([H])C=1[H])O[C@]1([H])[C@@]([H])(C([H])([H])O[H])O[C@]([H])([C@]1(C([H])([H])[H])F)N1C([H])=C([H])C(N([H])C1=O)=O
|
| InChi Key |
IBMLPFZASPUMOW-IAAJYNJHSA-N
|
| InChi Code |
InChI=1S/C22H29FN3O9P/c1-13(2)32-19(29)14(3)25-36(31,34-15-8-6-5-7-9-15)35-18-16(12-27)33-20(22(18,4)23)26-11-10-17(28)24-21(26)30/h5-11,13-14,16,18,20,27H,12H2,1-4H3,(H,25,31)(H,24,28,30)/t14-,16+,18+,20+,22+,36?/m0/s1
|
| Chemical Name |
propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-2-(hydroxymethyl)-4-methyloxolan-3-yl]oxy-phenoxyphosphoryl]amino]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~188.88 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8888 mL | 9.4438 mL | 18.8875 mL | |
| 5 mM | 0.3778 mL | 1.8888 mL | 3.7775 mL | |
| 10 mM | 0.1889 mL | 0.9444 mL | 1.8888 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
